IHC

EGFR exon 19

Detects deletions or mutations in exon 19 of the EGFR gene, which are common activating mutations in non-small cell lung carcinoma (NSCLC). These mutations predict sensitivity to EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib, and afatinib, aiding in targeted therapy selection and prognosis assessment.

Full Description

Detects deletions or mutations in exon 19 of the EGFR gene, which are common activating mutations in non-small cell lung carcinoma (NSCLC). These mutations predict sensitivity to EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib, and afatinib, aiding in targeted therapy selection and prognosis assessment.

Methodology

IHC

Specimen Requirements

Tissue Block: Formalin-fixed, paraffin-embedded (FFPE) tumor block preferred. Unstained Slides: Recommended 2 charged slides per stain requested (minimum of 1 slide per stain), baked or unbaked. Fixation: Tissue must be fixed in 10% neutral buffered formalin for 6–72 hours.

Storage and Transportation

Use cold pack for transport. Make sure cold pack is not indirect contact with specimen.

Turnaround Time

24 Hrs

CPT Codes

88342x1 or 88341x1